UPCC 18121: A Phase II Study of NirAparib Dostarlimab and Radiotherapy in Metastatic PD-L1 Negative or Immunotherapy-Refractory Triple-Negative Breast Cancer (NADiR)
Brief description of study
Please refer to Section 4 of the full protocol (Objectives) Please refer to Section 18.4 of the full protocol (Analysis of Primary Endpoints) Please refer to Section 18.5 of the full protocol (Analysis of Secondary and Exploratory Endpoints)
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 850234
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
